| Literature DB >> 28068099 |
Thomas J Anchordoquy, Yechezkel Barenholz1, Diana Boraschi2, Michael Chorny3, Paolo Decuzzi4, Marina A Dobrovolskaia5, Z Shadi Farhangrazi6,7, Dorothy Farrell8, Alberto Gabizon9, Hamidreza Ghandehari10, Biana Godin11, Ninh M La-Beck12, Julia Ljubimova13, S Moein Moghimi14, Len Pagliaro15, Ji-Ho Park16, Dan Peer17, Erkki Ruoslahti18, Natalie J Serkova, Dmitri Simberg.
Abstract
Remarkable progress has recently been made in the synthesis and characterization of engineered nanoparticles for imaging and treatment of cancers, resulting in several promising candidates in clinical trials. Despite these advances, clinical applications of nanoparticle-based therapeutic/imaging agents remain limited by biological, immunological, and translational barriers. In order to overcome the existing status quo in drug delivery, there is a need for open and frank discussion in the nanomedicine community on what is needed to make qualitative leaps toward translation. In this Nano Focus, we present the main discussion topics and conclusions from a recent workshop: "Mechanisms and Barriers in Nanomedicine". The focus of this informal meeting was on biological, toxicological, immunological, and translational aspects of nanomedicine and approaches to move the field forward productively. We believe that these topics reflect the most important issues in cancer nanomedicine.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28068099 PMCID: PMC5542883 DOI: 10.1021/acsnano.6b08244
Source DB: PubMed Journal: ACS Nano ISSN: 1936-0851 Impact factor: 15.881